Development of pH-responsive chitosan/heparin nanoparticles for stomach-specific anti-Helicobacter pylori therapy

被引:146
作者
Lin, Yu-Hsin [1 ]
Chang, Chiung-Hung [2 ]
Wu, Yu-Shiun [1 ]
Hsu, Yuan-Man [1 ]
Chiou, Shu-Fen [1 ]
Chen, Yi-Jen [1 ]
机构
[1] China Med Univ, Dept Biol Sci & Technol, Taichung 40402, Taiwan
[2] China Med Univ, Grad Inst Chinese Med Sci, Taichung 40402, Taiwan
关键词
Chitosan; Heparin; Peptic ulcers; Helicobacter pylori; Intercellular spaces; RAT GASTRIC TISSUE; BIOLOGICAL-ACTIVITY; GROWTH-FACTOR; HEPARIN; DELIVERY; MUCUS; DRUG; LOCALIZATION; CYTOTOXICITY; PATHOGENESIS;
D O I
10.1016/j.biomaterials.2009.02.036
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
The microorganism now known as Helicobacter pylori is considered to be an important factor in the etiology of peptic ulcers. It can secrete urease enzyme and buffer gastric acids to survive in the stomach. H. pylon can colonize the gastric mucosa and preferentially adheres near the cell-cell junctions of the gastric mucous cells. In this study, pH-responsive nanoparticles were produced instantaneously upon the addition of heparin solution to a chitosan solution with magnetic stirring at room temperature. The nanoparticles appeared to have a particle size of 130-300 nm, with a positive surface charge, and were stable at pH 1.2-2.5, allowing them to protect an incorporated drug from destructive gastric acids. We also demonstrated that the prepared nanoparticles can adhere to and infiltrate cell-cell junctions and interact locally with H. pylon infection sites in intercellular spaces. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3332 / 3342
页数:11
相关论文
共 56 条
[1]   Disruption of the epithelial apical-junctional complex by Helicobacter pylori CagA [J].
Amieva, MR ;
Vogelmann, R ;
Covacci, A ;
Tompkins, LS ;
Nelson, WJ ;
Falkow, S .
SCIENCE, 2003, 300 (5624) :1430-1434
[2]   MOLECULAR-WEIGHT DEPENDENCY OF THE HEPARIN POTENTIATED INHIBITION OF THROMBIN AND ACTIVATED FACTOR-X - EFFECT OF HEPARIN NEUTRALIZATION IN PLASMA [J].
ANDERSSON, LO ;
BARROWCLIFFE, TW ;
HOLMER, E ;
JOHNSON, EA ;
SODERSTROM, G .
THROMBOSIS RESEARCH, 1979, 15 (3-4) :531-541
[3]   Gastroretentive dosage forms:: Overview and special case of Helicobacter pylori [J].
Bardonnet, PL ;
Faivre, V ;
Pugh, WJ ;
Piffaretti, JC ;
Falson, F .
JOURNAL OF CONTROLLED RELEASE, 2006, 111 (1-2) :1-18
[4]  
BARRANCO SC, 1983, CANCER RES, V43, P1703
[5]  
BEIL W, 2007, PHYTOMEDICINE S1, V14, P5
[6]  
Bentolila A, 2000, POLYM ADVAN TECHNOL, V11, P377, DOI 10.1002/1099-1581(200008/12)11:8/12<377::AID-PAT985>3.0.CO
[7]  
2-D
[8]   HELICOBACTER-PYLORI AND THE PATHOGENESIS OF GASTRODUODENAL INFLAMMATION [J].
BLASER, MJ .
JOURNAL OF INFECTIOUS DISEASES, 1990, 161 (04) :626-633
[9]   Monocyte and macrophage killing of Helicobacter pylori:: Relationship to bacterial virulence factors [J].
Borlace, Glenn N. ;
Butler, Ross N. ;
Brooks, Doug A. .
HELICOBACTER, 2008, 13 (05) :380-387
[10]   Helicobacter pylori CagA induces AGS cell elongation through a cell retraction defect that is independent of Cdc42, Rac1, and Arp2/3 [J].
Bourzac, Kevin M. ;
Botham, Crystal M. ;
Guillemin, Karen .
INFECTION AND IMMUNITY, 2007, 75 (03) :1203-1213